Importantly, evACE2 achieved up to 4 to 5-fold greater efficacy in blocking the infection of pseudotyped SARS-CoV-2 variants that express S protein mutants from B1.1.7 (α variant), B1.351 (β variant), and B.1.617.2 (δ variant) when compared to WT (Fig. 2g). Here, PROS1 is linked to infection.